FDA Approves Duzallo (lesinurad and allopurinol) for Hyperuricemia in Patients with Uncontrolled Gout

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2017– Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced Duzallo was approved by the U.S. Food and Drug Administration (FDA) as a once-daily oral treatment for hyperuricemia associated with…

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us